New Six-year Ocrevus (Ocrelizumab) Data Showed That Earlier Initiation and Continuation of Treatment Reduced...
Post-hoc analysis from a Phase III open-label extension study showed a 42% reduction in the risk of PPMS patients needing a wheelchair after...